Lexicon Pharmaceuticals gains FDA approval for heart failure drug
Lexicon Pharmaceuticals aiming to commercialise their recently approved heart failure drug in June, after receiving approval from the US FDA based on significant findings from two Phase III trials.
The US FDA has now approved an oral tablet for the treatment of heart failure from Lexicon Pharmaceuticals. Sotagliflozin, under the brand name INPEFA™, is taken once a day, to help reduce the risk of death from a cardiovascular event, hospitalisation due to heart failure, and urgent heart failure visits in adults diagnosed with heart failure, type 2 diabetes mellitus, chronic kidney disease, and other conditions leading to a greater risk of cardiovascular disease.
The approval covers a range of heart failure patients, including all of left ventricular ejection fraction (LVEF), and patients with or without diabetes.
“The approval of INPEFA along with the breadth of the label, is a major milestone in Lexicon’s path to fulfilling its mission of pioneering medicines that transform patients’ lives,” explained Lonnel Coats, Lexicon pharmaceutical’s Chief Executive Officer. “We expect this important innovation to be commercially available in the U.S. market by the end of June 2023.”
Sotagliflozin underwent the testing that eventually gained the approval in two randomised, double-blind, placebo-controlled Phase III clinical trials studying cardiovascular outcomes in patients who had heart failure or were at risk of heart failure, SOLOIST-WHF and SCORED. The trials included nearly 12,000 people.
In the SOLOIST-WHF trial, the drug was shown to significantly reduce the number of hospitalisations and urgent visits for heart failure, and cardiovascular death by 33% compared to the placebo group.
Sotagliflozin is part of the SGLT2 and SGLT1 class of inhibitors that are recommended for the treatment of heart failure by the American Heart Association (AHA), the American College of Cardiology (ACC), and the Heart Failure Society of America (HFSA) in their joint 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Experts from the associations decree that SGLT2 inhibitors in particular should be used in all patients with heart failure with preserved ejection fraction who are determined as stable during hospitalisation.
“Based on outcomes observed in the SOLOIST-WHF study, initiating treatment with INPEFA prior to or upon hospital discharge has the potential to reduce the burden of readmissions on patients, caregivers, providers, and health systems,” stated Craig Granowitz, Lexicon’s Senior Vice President and Chief Medical Officer. “With today’s FDA approval, INPEFA is now a valuable option for physicians to consider when treating patients transitioning out of the hospital and working to break the cycle of repeated hospitalisations.”
With this approval, Lexicon Pharmaceuticals hope that their treatment will be available for use by June 2023, with a comparable market pricing package for heart failure medications.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance